Medications Available for Weight Reduction in Elective Total Joint Arthroplasty.

JBJS Rev · Jun 2020 · Review

Amanatullah DF, Ohanisian L, Bailony R

1Stanford Hospital and Clinics, Redwood City, California 2Charles E. Schmidt College of Medicine

Adult Reconstruction

SUMMARY — THE REDUCTIONReviews the six FDA-approved anti-obesity medications as potential tools to optimize high-BMI patients' weight before elective joint arthroplasty and reduce postoperative complications.
Abstract, as published

Arthroplasty in patients with elevated body mass index results in increased rates of reoperation, instability, revision, and infection. Preoperative weight loss may reduce the complication rate associated with orthopaedic surgery. In addition to lifestyle modification, anti-obesity medications are available to help patients to reduce their preoperative weight. Currently, there are 6 U.S. Food and Drug Administration (FDA)-approved anti-obesity medications in the United States: phentermine, orlistat, phentermine with topiramate extended release (ER), lorcaserin, sustained release (SR) naltrexone with bupropion, and liraglutide. Anti-obesity medications potentially provide a new way to optimize patients before surgery and to ensure successful recovery postoperatively.

Featured in the 2026-09-12 issue.

← Factors predisposing to dislocation after primary total hip a…Medical Weight Optimization for Arthroplasty Patients: A Prim… →

The Reduction is a free email digest of newly published orthopaedic literature — a handful of new papers in the subspecialties you choose, each summarized like this one. Subscribe free or browse the archive.